

NeoplasmsCancer

Study to Explore the Mechanism of Acquired Immune Escape In Participants With Metastatic Cancer Progressing on CPI Therapy

Trial Status
Completed

Trial Runs In
5 Countries

Trial Identifier
NCT03333655 ML40108

The information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

Official Title:

A Multicenter Study to Explore the Mechanism of Acquired Immune Escape In Patients With Metastatic Cancer Progressing on Checkpoint Inhibitor Therapy

Trial Summary:

The purpose of this study is to identify mechanisms associated with acquired immune escape by comparing baseline and at-progression tissue samples from participants who derive clinical benefit from CPI treatment of metastatic cancer or hematologic malignancies.

Hoffmann-La Roche
Sponsor

Phase 4
Phase

NCT03333655 ML40108
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
18 Years

Healthy Volunteers
No

Inclusion Criteria:

- Response assessment of complete response (CR), partial response (PR), or long-term stable disease (SD) for >6 months with a cancer immunotherapy treatment for metastatic cancer or hematologic malignancies either through a marketed CPI or through participation in a Roche/Genentech CPI clinical trial.
- Availability of tissue sample.

ForPatients

by Roche

Exclusion Criteria:

- Pregnant, lactating, or intending to become pregnant during the study.
- Participants receiving CPI treatment as part of a non-Roche/Genentech clinical trial.